HNP-1 Reverses Hypertensive Left Ventricular Hypertrophy by Inhibiting the NF-кB Signaling Pathway

Background: Human neutrophil peptide-1 (HNP-1) is a commonly investigated therapeutic agent. However, its role in hypertensive left ventricular hypertrophy (HLVH) remains unclear. Methods: We measured HNP-1 levels patients with hypertension and treated HLVH rat H9c2 cell models HNP-1. Cardiomyocyte indexes (i.e., single-cell surface area, fibrosis BNP levels, β-MHC levels) were hematoxylin-eosin Masson’s trichrome staining WB. NF-кB signaling factors IKKβ, p-IKKβ, IкBα, p-IкBα, p65, p-p65) WB qPCR. Finally, inflammatory IL-6, IL-1α, TNF-α) ELISA. Results: lower the exposure than control groups (M (95% CI), 48.83 (45.64–52.26) vs. 59.03 (55.62–62.54), P = 0.000). Diminished was associated occurrence patients. revealed elevated cardiomyocyte factors. each treatment group showed of aforementioned indices observed model groups. Conclusion: risk factor for HLVH. may reverse by inhibiting pathways.